Production of functional chimaeric mouse/human antibody

Area of Science:

• Immunology
• Biotechnology
• Molecular Biology

Background:

• Immunotherapy, particularly using monoclonal antibodies, is gaining renewed interest for disease control.
• Human immunoglobulin (Ig) is preferred for therapeutic interventions due to better compatibility and lower immunogenicity compared to other species.
• Ethical constraints and technical challenges limit obtaining specific human antibody-producing cell lines for therapeutic use.

Purpose of the Study:

• To develop a method for producing human antibodies with desired specificities for therapeutic applications.
• To overcome limitations in human immunization protocols for generating specific antibodies.
• To construct and characterize novel chimeric antibodies combining mouse and human immunoglobulin components.

Main Methods:

• Constructed immunoglobulin genes by joining mouse variable regions (specific for trinitrophenyl - TNP) with human constant regions (mu and kappa).
• Utilized gene engineering techniques to create 'chimaeric' immunoglobulin genes.
• Expressed these genes to produce functional TNP-binding chimaeric IgM antibodies.

Main Results:

• Successfully constructed and expressed functional chimaeric immunoglobulin genes.
• Produced novel chimaeric IgM antibodies capable of binding the hapten trinitrophenyl (TNP).
• Reported initial characterization of the properties of these newly developed chimaeric IgM antibodies.

Conclusions:

• Chimeric antibodies, combining mouse variable regions with human constant regions, offer a viable strategy to circumvent challenges in human antibody production.
• This approach enables the generation of human antibodies with specificities not easily attainable through conventional human immunization.
• The developed TNP-binding chimaeric IgM represents a significant step towards engineering therapeutic antibodies for human immunotherapy.